Our leadership team has extensive experience in developing, obtaining regulatory approvals for and successfully commercializing a variety of oncology products. In total, they have decades of combined experience spanning a range of cancers and other diseases.

Lonnie Moulder

Chief Executive Officer

Leon (Lonnie) O. Moulder, Jr. has served as Chief Executive Officer and as a member of our Board of Directors since co-founding TESARO in March 2010. From April 2009 to January 2010, Mr. Moulder served as Vice Chairman of the Board of Directors and President and Chief Executive Officer of Abraxis BioScience, Inc., a biotechnology company, and as president and Chief Executive Officer of its wholly owned operating subsidiary, Abraxis BioScience, LLC, and the Abraxis Oncology division. Before that, Mr. Moulder served as Vice Chairman and Executive Vice President of Eisai Corporation of North America, from January 2008 until January 2009, following Eisai Co. Ltd.'s acquisition of MGI PHARMA, a pharmaceutical company, in January 2008. Mr. Moulder served as President and Chief Executive Officer and as member of the Board of Directors of MGI PHARMA from May 2003 through January 2008. Mr. Moulder joined MGI PHARMA in September 1999 as Executive Vice President and was promoted to President and Chief Operating Officer in May 2002. Mr. Moulder earned a bachelor of science in pharmacy from Temple University and master of business administration from the University of Chicago. Mr. Moulder currently serves as chairman of the board of directors of Trevena; on the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization (BIO); as a trustee of Temple University and is on the Board of the Fox Chase Cancer Center. He also served as a Director of Cubist Pharmaceuticals through the sale of the company in 2015.